Arjuna Natural Pvt. Ltd. announced the results of a new study – currently under peer-review – that demonstrates the analgesic activity of its proprietary blend of three botanicals called Rhuleave-K.
Photo © iStockphoto.com/monkeybusinessimages
Arjuna Natural Pvt. Ltd. (Kerala, India) announced the results of a new study – currently under peer-review – that demonstrates the analgesic activity of its proprietary blend of three botanicals called Rhuleave-K. The announcement comes in advance of the ingredient’s launch at SupplySide West 2019 in Las Vega, NV.
The study found that Rhuleave-K was equally as effective as the standard over-the-counter (OTC) acetaminophen (Tylenol) in reducing pain intensity and providing pain relief for acute musculoskeletal pain within two hours of consumption. This is significant because prolonged use of OTC analgesics like acetaminophen and ibuprofen may induce liver and renal toxicity, as well as gastrointestinal damage.
“We know it is becoming more critical to develop all-natural pain relief formulas,” said Nipen Lavingia, brand innovation advisor for Arjuna Natural based in Dallas, TX, in a press release. “This study is especially significant since there are few natural products available for immediate pain relief that have similar benefits as OTC analgesics.”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.